Clinical Practice GuidelinesAASLD 2023 Pathway
Clinical Practice Guidelines • AASLD 2023

AASLD 2023 Practice Guidance on the Clinical Assessment and Management of MASLD/MASH

Three-setting clinical pathway linking primary care FIB-4 screening, secondary VCTE or ELF risk tiers, and GI/hepatology specialist staging.

What This Means for Patients

Think of the AASLD pathway as a traffic map between your regular doctor and a liver specialist. A FIB-4 under 1.3 lets you stay safely with primary care and recheck in 1 to 3 years. A FIB-4 above 2.67 sends you straight to a liver specialist. If you land in the middle zone (1.3 to 2.67), a second test — FibroScan (VCTE) or the ELF blood score — sorts out whether your scarring is low, intermediate, or high risk.

Clinical Risk-Stratification Pathway Across Care Settings

Entry Criterion: Suspicion for Fatty Liver Disease (steatosis on imaging or elevated cardiometabolic risk factors such as T2D, obesity, or metabolic syndrome)
Primary Care or Non-GI/Hepatology Care Goal: Exclude advanced fibrosis in low-prevalence populations
Primary risk assessment, eg, FIB-4
FIB-4 <1.3 (No) Low Risk
FIB-4 1.3–2.67 (Yes) Secondary Test →
FIB-4 >2.67 Direct GI/Hep Referral →
↓ If FIB-4 <1.3
Reassess periodically:
  • FIB-4 every 1–2 years if T2D/pre-T2D or ≥2 metabolic risk factors
  • FIB-4 every 2–3 years if no T2D and <2 metabolic risk factors

Note: If persistent ↑ALT and AST → Consider referral to GI/Hepatology.

All Patients (Foundational Care):
  • Cardiometabolic risk reduction and preferential use of medicines with potential MASLD benefit
  • Ongoing assessment of alcohol intake
  • Lifestyle management
Either Care Setting Primary or non-GI/hepatology care as well as GI/Hepatology care
Secondary Risk Assessment (if FIB-4 ≥1.3)

Perform VCTE™ (kPa) or ELF™ score:

Risk Level VCTE™ (kPa) or ELF™
Low <8.0 <7.7
Intermediate 8–12 7.7–9.8
High >12 >9.8
↓ Routing by Risk Tier
Low Risk (<8.0 kPa or <7.7) PCP Follow-Up (2–3 y)
Intermediate (8–12 kPa / 7.7–9.8) Referral to GI/Hep
High (>12 kPa or >9.8) Referral to GI/Hep
GI / Hepatology Care Goal: Identify/manage patients with “at-risk” MASH or cirrhosis
Specialist Assessment:
  • Review/perform primary/secondary risk assessment
  • Consider additional stratification with MRE, cT1
Low risk PCP follow-up or reassess
↓ If Intermediate / High Risk
Consider Liver Biopsy if:
  • Indeterminate NITs
  • Diagnostic uncertainty
  • Persistently ↑ALT and AST

Suspected cirrhosis (clinical, imaging, or ELF™ >11.3) → Proceed directly to Stage 4 / Cirrhosis-based management

Management by Biopsy / Clinical Staging:
Stage 0–1 Reassess in 2–3 years
Stage 2–3 Reassess annually • Consider pharmacotherapy
Stage 4 Cirrhosis-based management
2024–2025 AASLD Companion Guidance: AASLD subsequently published its 3-part GRADE NILDA Practice Guidelines (2025) and Biopsy-Free MASH Pharmacotherapy Guidance (defining VCTE 8–15 kPa, MRE 3.1–4.4 kPa, and ELF 9.2–10.5 cutoffs for non-cirrhotic F2–F3 drug selection without biopsy).